Brind.

Microbiotica Raises £36m Series C Funding Led by British Business Bank

1 report, 1 independent Updated Fri 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Microbiotica closed a £36 million Series C financing round. The round was led by British Business Bank, with participation from Tencent and IP Group plc. The capital is intended to support the advancement of MB310 into Phase 2 clinical development for ulcerative colitis.

From investegate.co.uk

Why it matters

Some supportBrind's analysis of the reports

The funding supports the clinical progression of Microbiotica, a biopharma company that is developing precision microbiome medicines. As a result, IP Group plc increased its beneficial holding in Microbiotica to 16.4%, valued at £24.1 million.

From investegate.co.uk

Who's involved

  • TencentParticipated in the Series C financing round of Microbiotica.
  • British Business BankLed the Series C financing round for Microbiotica.
  • IP GroupIncreased its beneficial holding in Microbiotica through the financing.

Who could feel it

Possible knock-on effects

These are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.

  • TencentSpeculative

    Tencent might see changes in the segment of its business due to participation in Microbiotica's financing.

  • British Business BankSpeculative

    British Business Bank could fulfill its investment mandate by successfully leading the financing round.

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped